论文部分内容阅读
目的:观察奥扎格雷钠联合依达拉奉治疗急性脑梗死的临床疗效。方法:将160例急性脑梗死患者随机分为治疗组和对照组,每组各80例,治疗组采用注射用奥扎格雷钠联合依达拉奉治疗,对照组仅采用注射用奥扎格雷钠治疗,观察两组患者入院及治疗14d后临床疗效,神经功能缺损评分变化并进行对比分析。结果:治疗组的显效率为85.9%(67/78),对照组显效率为70.9%(56/79),两组显效率有显著性差异(x2=5.12,P=0.022),两组患者治疗14d后,神经功能的恢复情况与治疗前相比均有显著性差异(P<0.05),且治疗组与对照组治疗后比较有显著性差异,具有统计学意义(P<0.05)。结论:奥扎格雷钠联合依达拉奉治疗急性脑梗死较单独使用奥扎格雷钠疗效显著,是治疗急性脑梗死的有效方法。
Objective: To observe the clinical efficacy of sodium ozagrel combined with edaravone in the treatment of acute cerebral infarction. Methods: One hundred and sixty patients with acute cerebral infarction were randomly divided into treatment group and control group, 80 cases in each group. Ozagrel sodium and edaravone for injection were used in the treatment group. Ozagrel sodium for injection The clinical efficacy and neurological deficit score of the two groups were observed and compared 14 days after admission and treatment. Results: The effective rate was 85.9% (67/78) in the treatment group and 70.9% (56/79) in the control group, with significant difference between the two groups (x2 = 5.12, P = 0.022) After 14 days of treatment, the recovery of neurological function was significantly different from that before treatment (P <0.05), and there was significant difference between the treatment group and the control group after treatment (P <0.05). Conclusion: Ozagrel combined with edaravone has a significant effect on the treatment of acute cerebral infarction compared with Ozagrel alone, which is an effective treatment for acute cerebral infarction.